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Results We identified eight retrospective published studies, 
two prospective published studies, and five registered clini-
cal trials. Moreover, we analyzed the content of four wide-
spread international guidelines.
Conclusions Our critical review confirms the lack of high-
quality data to recommend everolimus as the first line ther-
apy for pNETs. The ongoing clinical trials reported in this 
review will hopefully help clinicians, in the near future, to 
better evaluate the role of everolimus as the first line ther-
apy for pNETs. However, at the moment, there is already 
enough evidence to recommend everolimus as the first line 
therapy for patients with symptomatic malignant unresect-
able insulin-secreting pNETs, to control the endocrine syn-
drome regardless of tumour growth.
Keywords Everolimus · Neuroendocrine tumours · mTOR 
inhibitors · Therapy
Introduction
Pancreatic neuroendocrine tumours (pNETs) are rare 
tumours with an incidence rate that is steadily increasing 
in different countries (Capelli et al. 2012; Scherubl et al. 
2013; Tsai et al. 2013; Yao et al. 2008a).
Clinical manifestations are sometimes hormonal related, 
due to secretion by the tumour (i.e., gastrin, insulin, vaso-
active intestinal peptide, etc). However, most of pNETs are 
discovered incidentally, or as a result of the mass effect of 
the primary tumour and distant metastases; these may be 
found at diagnosis in about half of the patients with non-
functioning pNETs (Frilling et al. 2014; Halfdanarson et al. 
2008; Ito et al. 2012a; Yao et al. 2008a).
pNETs generally show moderate biological aggres-
siveness and a slow rate of growth. Indeed, although 
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surgical resection is the main therapeutic approach for 
functioning pNETs, some evidences support the safety of 
a conservative approach for asymptomatic sporadic non-
functioning pNETs with a tumour size of 2 cm or less 
(Boninsegna et al. 2012; Guo and Wu 2013; Knigge and 
Hansen 2012).
Numerous factors for predicting survival have been 
identified, including age at diagnosis, functional status, 
Ki-67 index, and stage (Halfdanarson et al. 2008). Five-
year survival rate is approximately 80–90% for localized 
pNETs, dropping to ~40% for patients with metastatic 
disease (Cherenfant et al. 2013; Lawrence et al. 2011).
Treatment of patients with advanced/progressive 
pNETs is challenging and includes locoregional proce-
dures to manage liver metastases and systemic therapies 
for diffuse metastatic disease with high and/or rapidly 
progressing tumour burden (Pavel et al. 2016). Systemic 
treatments encompass somatostatin analogs (SSAs), pep-
tide receptor radionuclide therapy (PRRT), interferon-
alpha therapy, conventional chemotherapy, and targeted 
therapies.
In the last few years, the therapeutic approach for 
advanced pNETs has dramatically changed. Both suni-
tinib and everolimus, which target respectively multiple 
tyrosine kinase receptors and the mTOR signalling path-
way, have been approved for the treatment of advanced 
pNETs (Raymond et al. 2011; Yao et al. 2011).
In the EU, everolimus is currently authorised for the 
“treatment of unresectable or metastatic, well- or moder-
ately differentiated neuroendocrine tumours of pancreatic 
origin in adults with progressive disease” (http://www.
ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/001038/WC500022814.
pdf).
Promising efficacy has been shown for temozolomide, 
alone or combined with capecitabine (Ekeblad et al. 2007; 
Strosberg et al. 2011), and for radionuclide therapy with 
177Lu-Dotatate (Strosberg et al. 2017). However, the opti-
mal sequence of these different treatments has not been 
defined to date, because studies specifically designed for 
identifying which therapy is to be preferred for a specific 
moment of the disease course are lacking, and data from 
ongoing trials on this issue are still awaited.
With the aim to shed light on the treatment algorithm for 
advanced pNETs, we performed an up-to-date critical review 
taking into account the results of both retrospective and pro-
spective published studies on everolimus as the first line 
therapy for pNETs, and the recommendations of widespread 
international guidelines on the clinical management of NETs. 
In addition, we performed an extensive search on the Clinical 
Trial Registries databases worldwide, to gather information 
on the ongoing clinical trials related to this specific topic.
Molecular background
Activation of the mTOR pathway in pNETs
The phosphatidylinositol 3-kinase(PI3K)-AKT pathway 
is a major mediator of the intracellular signalling network 
regulating essential cellular functions such as metabo-
lism, proliferation, growth, and apoptosis (Altomare and 
Testa 2005). PI3K is recruited to the plasma membrane in 
response to extracellular signals, mainly growth factors 
(i.e., VEGF, PDGF, IGF-1, etc), which bind to specific 
cell membrane receptors thus activating the PI3K/AKT 
pathway cascade (Fig. 1).
The serine/threonine kinase mTOR (mammalian target 
of rapamycin) is the most important downstream compo-
nent of the PI3K/AKT signalling pathway (Vignot et al. 
2005). mTOR is constituted by two separate complexes: 
mTOR complex 1 (mTORC1) and complex 2 (mTORC2). 
Key functions of mTORC1 are largely identified, since it 
has been shown to essentially promote cell growth and 
proliferation and to be sensitive to rapamycin inhibitory 
action. mTORC2 role is less well defined: it is rapa-
mycin insensitive (Zeng et al. 2007), and regulates actin 
cytoskeleton and cell migration (Jacinto et al. 2004).
The development of human cancers, including pNETs, 
may be a consequence of overexpressed extracellular 
signals or aberrant activity of cell membrane receptors 
and their related downstream signalling. For instance, a 
downregulation of PTEN and TSC2, both of which nega-
tively regulate mTOR signalling, was reported in primary 
pNETs (Missiaglia et al. 2010). Somatic mutations of 
genes coding components of the PI3K/AKT/mTOR path-
way have been reported in 15% of non-familial pNETs 
(Jiao et al. 2011). Activation of AKT was observed in 
28 out of 46 NETs, thus suggesting a role of p-AKT in 
NET tumourigenesis (Ghayouri et al. 2010). The expres-
sion rates of both mTOR and activated mTOR (p-mTOR) 
ranged from 45.0 to 70.8% and from 44.4 to 61.8%, 
respectively, in a retrospective series of NETs (Zhou 
et al. 2010). All these evidences document a relevant role 
of the mTOR signalling in the pathogenesis of pNETs.
Everolimus and pNETs
Activity, efficacy, and safety
Rapamycin has immunosuppressive functions, and the 
protein complex named RAFT (rapamycin and FKBP12 
target), a mammalian homolog of the yeast TOR pro-
teins (Heitman et al. 1991; Kunz et al. 1993), has been 
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Fig. 1  Simplified representation of the PI3K-AKT-mTOR pathway and mechanism of action of everolimus
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suggested as its direct target in humans (Sabatini et al. 
1994). Rapamycin and its analogs (i.e., everolimus) bind 
to an intracellular receptor, the FK506-binding protein 
(FKBP) (Harding et al. 1989; Siekierka et al. 1989), and 
this FKBP-rapamycin complex interacts with mTOR 
leading to inactivation of the mTOR signalling through 
dephosphorylation of both downstream effectors (4EBP1 
and S6K1) of mTORC1 (Meric-Bernstam et al. 2012). 
mTOR signalling is implicated in cancer proliferation 
and progression (Osaki et al. 2004; Wullschleger et al. 
2006), and several studies documented that inhibition 
of the PI3K/AKT/mTOR pathway can be helpful for the 
treatment of patients with cancer, including pNETs.
In vitro, the activity of everolimus on the modulation 
of cell proliferation was demonstrated in BON1 cells, a 
human pNET cell line characterized by constitutive activa-
tion of the PI3K/AKT/mTOR pathway. In this study Zitz-
mann and coworkers (Zitzmann et al. 2007) observed that 
treatment with everolimus led to inhibition of cell growth 
by G0/G1 cell cycle arrest and promotion of apoptosis. 
Similarly, this antiproliferative effect was observed in INS1 
cells, a rat insulinoma cell line, where everolimus inhibited 
phosphorylation of both mTOR and its downstream target 
S6K1 (Grozinsky-Glasberg et al. 2008).
These evidences encouraged researchers to translate 
these findings into clinical settings. Yao and coworkers 
first demonstrated the efficacy and safety of everolimus in 
patients with advanced low- to intermediate-grade NETs 
(Yao et al. 2008b). They showed that everolimus in associa-
tion with octreotide LAR was well tolerated and provided 
promising antitumour activity: among the 30 patients with 
islet cell tumours, partial response was obtained in 27% 
and median progression-free survival (PFS) was 50 weeks. 
Thereafter, a phase 2 study confirmed the effectiveness 
of treatment with everolimus in patients with metastatic 
pNETs who progressed after cytotoxic chemotherapy (Yao 
et al. 2010). On May 2011, the food and drug administra-
tion approved everolimus for the treatment of progres-
sive pNETs, in case of unresectable locally advanced or 
metastatic disease. This approval was based on the find-
ings obtained in a randomized controlled phase 3 trial 
that compared the treatment with everolimus 10 mg/die 
(n = 207) to placebo (n = 203) in patients with advanced 
pNETs (Yao et al. 2011). Investigators reported that treat-
ment with everolimus was associated with a 65% reduction 
in the risk of progression or death. Ten (5%) out of 207 
patients receiving everolimus obtained an objective tumour 
response, the main antitumour activity of everolimus was 
related to a stabilization of disease (73% of cases), while 
some degree of tumour shrinkage was observed in 64%.
Efficacy of everolimus has also been reported with 
extra-pancreatic NETs. A recent systematic review evalu-
ated the efficacy of everolimus for extra-pNETs retrieving 
22 studies, corresponding to 456 patients with NETs origi-
nating from several primary sites, including small bowel, 
lung, and colon/rectum (Faggiano et al. 2016). These find-
ings were confirmed by a randomized, double-blind, pla-
cebo-controlled, phase 3 trial that investigated the efficacy 
and safety of everolimus in patients with non-functioning 
well-differentiated (G1 or G2) NETs of gastrointestinal 
(n = 175) or lung origin (n = 90). Treatment with everoli-
mus reduced risk of progression by 44 and 50% in gastroin-
testinal and lung NETs, respectively (Yao et al. 2016).
All studies confirmed that everolimus was generally well 
tolerated, and grade 3–4 drug-related adverse events were 
not frequent. The most common grade 3–4 adverse events 
were stomatitis (7%), anemia (6%), and hyperglycaemia 
(5%) (Yao et al. 2011). The drug-related toxicity profile is 
a main issue to consider when starting a new therapy line. 
For instance, compared to everolimus, octreotide and lan-
reotide are generally well tolerated. The most common 
adverse events in patients treated with SSAs are moderate 
and regard the gastrointestinal tract (diarrhoea, abdomi-
nal pain, and cholelithiasis). The frequency of grade 3–4 
adverse events in patients treated with chemotherapy (i.e. 
streptozotocin, 5-FU, or doxorubicin), instead, is higher 
(about 20%) than that observed for everolimus and usually 
includes hematologic, heart, and kidney toxicities (Valle 
et al. 2014).
Despite its well-established antitumour activity, treat-
ment with everolimus is not effective in a subset of patients, 
possibly due either an innate or an acquired tumour resist-
ance. Molecular events underlying resistance to everolimus 
are not completely known, but probably descend from the 
activation of compensatory feedback loops, and crosstalk 
between the PI3K/AKT/mTOR cascade and other path-
ways (Burris 2013; Markman et al. 2010). Given the pres-
ence of mechanisms of resistance, novel PI3K/AKT/mTOR 
inhibitors (Vandamme et al. 2016) and/or drugs with dual 
target inhibitory effects are currently under evaluation.
It should be emphasized that all the evidences about the 
efficacy of everolimus in pNETs come from patients with 
sporadic tumours, whereas the drug has not formally been 
evaluated in inherited disorders such as multiple endocrine 
neoplasia type 1 (MEN1) (Yates et al. 2015), and extrapo-
lations from results obtained in patients with non-familial 
pNETs deserve caution.
Mutations in the mTOR pathway have been found in 
~15% of pNETs, making everolimus an attractive thera-
peutic option in this setting. Indeed, everolimus has been 
studied in the widest development program for a new drug 
in pNETs. A pathophysiological rationale for associating 
everolimus and SSAs has been hypothesized, since the 
upregulation of the IGF1 pathway has been proposed as a 
potential resistance mechanism for mTOR inhibitors. Fur-
thermore, SSAs reduce serum IGF1 levels, which, in turn, 
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seem to activate mTOR and to increase cell proliferation 
(O’Reilly et al. 2006; Pollak et al. 1989; von Wichert et al. 
2000). From a clinical point of view, in the phase 2 open-
label, nonrandomized study RADIANT-1 (Yao et al. 2010), 
which was not designed to evaluate whether everolimus 
combined with SSAs was superior to everolimus mono-
therapy, the combined therapy resulted in a longer PFS 
(16.7 vs. 9.7 months in the everolimus monotherapy arm). 
This disease-stabilizing activity was confirmed in the rand-
omized phase 3 clinical trial RADIANT-3 (Yao et al. 2011), 
which documented a significantly longer PFS in patients 
with pNETs randomized to the association of everolimus 
and octreotide (11 vs. 4.6 months in the octreotide alone 
arm). In addition, the combination of everolimus with lan-
reotide suggested efficacy in a retrospective cross-sectional 
analysis, without unexpected toxicities, apparently through 
a synergistic effect (Capdevila et al. 2015). The possibil-
ity of enhanced efficacy with SSAs combined with everoli-
mus is actually being explored in randomized clinical trials, 
such as the phase 2 study COOPERATE-2 and the LUNA 
clinical trial, whose definitive results are eagerly awaited, 
even if preliminary data are disappointing. However, in 
daily clinical practice, SSAs and everolimus are often given 
concurrently for patients with pNETs, especially function-
ing pNETS.
Predictive factors of response to everolimus
As cancer therapies are expensive and often associated 
with significant adverse events, identifying factors able 
to predict which patients will experience useful clinical 
responses is of high relevance to patients, clinicians, and 
health authorities.
Several studies investigated the role of various predic-
tors of response to mTOR inhibitors, including clinical, 
biological, and histological factors (Zatelli et al. 2016).
Response to mTOR inhibitors has been associated with 
the expression levels of the mTOR pathway components, 
which have been evaluated by immunohistochemistry 
(IHC) and molecular studies on tissue specimens. Recently, 
effectiveness of everolimus was positively correlated to the 
IHC overexpression of phosphorylated p70S6K (Benslama 
et al. 2016). Response to mTOR inhibitors seems to cor-
relate with the presence of mutations of genes involved in 
the PI3K/AKT/mTOR pathway (Meric-Bernstam et al. 
2012). Sensitivity to rapamycin was related to genomic 
aberration of PIK3CA and/or PTEN (Meric-Bernstam et al. 
2012), while resistance to everolimus has been observed in 
patients with oncogenic KRAS mutation (Di Nicolantonio 
et al. 2010). Recently, in patients with pNETs responsive-
ness to everolimus treatment has been correlated with a 
higher protein levels of the IGF1 downstream signalling 
involved in mTOR pathway (Falletta et al. 2016).
At present, however, IHC studies and assessment of 
mutational status of the mTOR signalling by DNA/pro-
tein evaluation are not routinely recommended to drive the 
selection of patients that may benefit from treatment with 
everolimus.
Methodology for literature search strategy
Definition of first line
Since available data come from studies on patients who fre-
quently received SSAs prior, we considered “Everolimus 
as first line” in the following conditions: Everolimus given 
alone or in association with other therapies (including 
chemotherapy and SSAs), in patients who did not receive 
any previous therapies other than SSAs.
Current knowledge
Published retrospective and prospective studies Four 
investigators (M.G., P.M., G.F., and F.R.) independently 
searched the Medline database (via the PubMed interface) 
to identify potentially relevant articles on the therapeutic 
use of everolimus (alone or associated with other treat-
ments) as a first line therapy for pNETs. The search was 
last updated February 15th, 2017. Only articles published 
in English language were considered. The search strategy 
included the following terms: “neuroendocrine tumour”, 
“neuroendocrine carcinoma”, “pancreatic neuroendocrine 
tumour”, “pancreatic neuroendocrine carcinoma”, “everoli-
mus”, and “RAD001”.
Articles were considered without any restriction, and only 
Editorials and Letters were excluded. Single case reports 
were excluded and only studies describing two or more 
patients previously treated with everolimus for a pNET were 
considered. The selected abstracts were then further assessed 
for a full-text evaluation. Additional studies were identified 
by reviewing the references of all selected articles.
International guidelines Among the numerous available 
guidelines on the clinical management of NETs, issued by 
different scientific societies, four investigators (MG, P.M., 
G.F., and F.R) selected the 4 guidelines more frequently 
used at their centers for decision-making.
Future perspectives
Registered clinical trials (ReCTs) To detect all potentially 
relevant ReCTs on everolimus (alone or in association) as 
the first line therapy for pNETs, two investigators (G.F. and 
F.R.) independently searched the U.S. National Institutes of 
Health Registry (https://clinicaltrials.gov/), and all the “Pri-
mary Registries” defined according the WHO International 
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Clinical Trial Registry Platform (ICTRP) (http://www.
who.int/ictrp/network/en/) (see Table 1). The search was 
last updated February 15th, 2017. ReCTs published in 
all the Official Languages of the Primary Registries were 
considered. The terms included for the search strategy are 
the same used for the “Published Prospective Clinical Tri-
als and Retrospective Studies”. Only ReCTs for which the 
study protocol clearly states that enrolled patients are not 
receiving nor had previously received, at any time, any 
treatment for pNETs, including chemotherapy, radiation 
therapy, antibody based therapy, targeted therapy, bio-
therapy, etc., but excluding SSAs, were included. For the 
ReCTs in which the study protocol inclusion and exclusion 
criteria were not unambiguous, the Principal Investigator 
and/or the Sponsor were contacted for further clarifications.
Results
Current knowledge
Published retrospective Studies
Overall, 8 retrospective studies were identified (Bernard 
et al. 2013; Capdevila et al. 2015; Ferrer-Garcia et al. 2013; 
Fiebrich et al. 2011; Kulke et al. 2009; Liu et al. 2016; Pan-
zuto et al. 2014; Tippeswamy et al. 2015), which included 
a total of 183 patients with pancreatic and 135 patients with 
extra-pancreatic NETs (see Table 2a).
Despite the methodological effort to specifically focus 
on studies on everolimus as the first line therapy, evaluation 
of efficacy of everolimus as the first line approach was pos-
sible in only 56 (17.6%) patients with pNETs of the studies 
identified. Most patients were treated with everolimus as a 
second line drug, after failure of the previous medical treat-
ments. Taking into account this limitation, treatment with 
everolimus led to disease stabilization in more than half of 
patients (Liu et al. 2016; Tippeswamy et al. 2015), and dis-
appearance of hypoglycaemic symptoms in malignant insu-
linomas (Fiebrich et al. 2011).
Published prospective studies
Only two prospective studies aimed to assess the efficacy of 
everolimus as the first line for patients with pNETs, namely 
the RADIANT-3 and the ITMO group study (see Table 2b).
Among the patients included in the RADIANT-3, 204 
patients (103 in the everolimus arm and 101 in the placebo 
arm) were chemotherapy-naïve, and 206 patients (104 in 
the everolimus arm and 102 in the placebo arm) had been 
previously treated with chemotherapy (Yao et al. 2011).
A subgroup analysis of RADIANT-3 was performed 
aiming to assess the role of chemotherapy on the efficacy 
of everolimus (Lombard-Bohas et al. 2015). This suba-
nalysis demonstrated no relevant difference of the efficacy 
of everolimus between patients previously treated with 
chemotherapy and those which were chemotherapy-naïve, 
according to the evaluation of local investigators as well as 
central reviewers. In particular, the median PFS in chem-
onaïve patients who received everolimus was 11.4 months 
for local investigators and 14 months for central review-
ers, whereas in non chemotherapy-naïve patients who 
received everolimus was 11 months for local investiga-
tors and 11.4 months for central reviewers. The objec-
tive response rate (ORR) and disease control rate (DCR) 
showed no significant differences between the two groups. 
Therefore, data obtained from the RADIANT-3 suggest 
that everolimus is effective in patients with advanced, well, 
and moderately differentiated pNETs, both before and after 
chemotherapy.
The ITMO group study was focused on the use of 
everolimus as the first line in a patient population with 
NETs (Bajetta et al. 2014). Fifty patients with lung and 
gastroenteropancreatic (GEP) NETs were studied. Thirteen 
of them had carcinoid syndrome, while 14 patients had a 
pNET. None of the patients previously received any treat-
ment. During the study, patients were treated with everoli-
mus 10 mg/day and octreotide 30 mg/28 days. The ORR, 
which was the primary endpoint of the study, was 18% in 
the intent-to-treat population (ITT), formed by patients 
who received at least one dose of everolimus and 19.6% 
in the per-protocol population (PP). Four patients were 
excluded from PP analysis, one for major breach of the pro-
tocol and three because they had not reached the minimum 
Table 1  Primary registries of clinical trials defined according the 
WHO International Clinical Trial Registry Platform (ICTRP) (http://
www.who.int/ictrp/network/en/)
#
 Primary Clinical Trial Registry recognized by WHO and Interna-
tional Committee of Medical Journal Editors
Australian New Zealand Clinical Trials Registry (ANZCTR)
Brazilian Clinical Trials Registry (ReBec)
Chinese Clinical Trial Registry (ChiCTR)
Clinical Research Information Service (CRiS) - Republic of Korea
Clinical Trials Registry—India (CTRI)
Cuban Public Registry of Clinical Trials (RPCEC)
EU Clinical Trials Register (EU-CTR)
German Clinical Trials Register (DRKS)
Iranian Registry of Clinical Trials (IRCT)
Japan Primary Registries Network (JPRN)
ISRCTN  Registry#
Thai Clinical Trials Registry (TCTR)—Thailand
The Netherlands National Trial Register (NTR)
Pan African Clinical Trial Registry (PACTR)
Sri Lanka Clinical Trials Registry (SLCTR)
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established dose of everolimus. The analysis was not speci-
fied for patient subgroups according to the site of origin of 
the NET, but the authors stated that no statistically signifi-
cant differences in ORR were found for different locations 
of NETs. They also specified that, among patients with 
pNETs, 2 partial responses (PR) were observed, while none 
showed a complete response (CR). As for the secondary 
endpoints [Time To Progression (TTP), and Overall Sur-
vival (OS)], no significant differences were observed after 
a median of 227 days (Bajetta et al. 2014). Even with the 
limitations of the study, such as the low number of subjects 
and the lack of a control group, the ITMO study Group 
suggests that combined therapy with everolimus/octreotide 
LAR can be effective as first line for patients with pNETs 
as well as with NETs of other origin.
International guidelines
To the purpose of this review, guidelines from the follow-
ing scientific societies were considered: ESMO (European 
Society for Medical Oncology), ENETS (European Neu-
roendocrine Tumour Society), NANETS (North American 
Neuroendocrine Tumour Society), and NCCN (National 
Comprehensive Cancer Network).
In 2012, immediately after the publication of the RADI-
ANT-3 trial, the ESMO updated its guidelines for GEP-
NETs (Oberg et al. 2012). Everolimus was mentioned as 
“another specific therapy” in the paragraph dedicated to the 
medical therapy for the management of advanced/meta-
static disease, currently registered for treatment of pancre-
atic NETs worldwide, to be used alone or in combination 
with a SSA. Indeed, SSAs were designed as “the recom-
mended the first line therapy in non-functioning as well as 
functioning progressive G1/G2 NETs”. Browsing through 
the ESMO treatment algorithm, however, everolimus 
appears as the first line therapy for G1/G2 (Ki-67: 2–20%) 
non-functioning pNETs (just like sunitinib), whereas—
among functioning pNETs—its first line use is hypoth-
esized for symptomatic treatment of insulinomas.
The 2010 edition of the NANETS consensus guidelines 
for the management of NETs simply mentioned everolimus 
as a drug that may control hypoglycaemia in patients with 
metastatic insulinomas (Kulke et al. 2010). Three years 
later, the updated version of NANETS guidelines had to 
take into account the publication of “a number of practice-
changing studies”, namely the completion of several phase 
3 trials evaluating octreotide, sunitinib, and everolimus. In 
the new document, indication for initiating targeted thera-
pies (or cytotoxic chemotherapy) in patients with advanced 
pNETs was defined “a controversial topic in the manage-
ment of NETs”. However, dealing with the management 
of advanced pNETs, everolimus (like sunitinib, hepatic 
artery embolization, or simple observation for a brief 
3-month period) was defined as a treatment to be consid-
ered in newly diagnosed patients with high-volume disease. 
Furthermore, therapy with everolimus was defined to be 
“recommended” in the event of progressive disease, and 
for hormonal syndrome control of insulinomas. Accord-
ing to the NANETS guidelines, however, lines of therapy 
for pNETs have not been definitely established, and “the 
proposed order of listing does not imply order of therapy” 
(Kunz et al. 2013).
Currently available NCCN guidelines for the manage-
ment of well-differentiated (Grade 1–2) pNETs were issued 
in 2016. According to these guidelines, everolimus (with 
or without SSAs) should be considered as first line therapy 
only in the management of locoregional unresectable dis-
ease and/or distant metastases in patients with: (1) sympto-
matic disease; or (2) clinically significant tumour burden; 
or (3) clinically significant progressive disease (NCCN 
2016). However, in the absence of prospective randomized 
trials, there is no clear recommendation for preferring 
everolimus as the first line choice over other choices such 
as sunitinib or cytotoxic chemotherapy or hepatic regional 
therapy or cytoreductive surgery/ablative therapy.
In the 2012 consensus guidelines from the ENETS, 
everolimus was mentioned as an option after failure of 
chemotherapy in pNETs, being considered as the first line 
therapy in exceptional cases as an alternative to locore-
gional therapies or chemotherapy (e.g., symptomatic, bulky 
disease or intolerance of ongoing therapy) (Falconi et al. 
2012). The panel did not recommend an early unselected 
use of the drug due to the lack of long-term toxicity data. 
Furthermore, everolimus was also suggested for the treat-
ment approach to liver metastases from pNETs, as an alter-
native to SSAs, chemotherapy, sunitinib, or PRRT (Pavel 
et al. 2012). Conversely, according to the last version of 
the ENETS guidelines for the management of distant meta-
static disease of NETs, everolimus (and sunitinib) can be 
considered a first line systemic, antiproliferative therapy 
for advanced and/or progressive non-functional G1/G2 
pNETs, representing one of the different treatment alterna-
tives, especially if SSAs are not an option, and if systemic 
chemotherapy is not feasible, not clinically required, or not 
tolerated (Pavel et al. 2016).
Future perspectives
Overall, 128 ReCTs were identified. Of the 128 ReCTs 
analyzed, only 4 matched the initial requirements, there-
fore, specifically dealing with the topic “Everolimus as first 
line therapy on pNETs”.
In brief, we detected 4 Phase 2 studies, and everoli-
mus is being employed: (1) alone; (2) in combination with 
octreotide and metformin; (3) in combination with temo-
zolomide; and (4) in combination with cisplatinum. Of the 
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4 ReCTs, 3 are still recruiting participants at the time of 
manuscript writing. Of the 5 ReCTs, 1 is not yet open for 
participant recruitment at the time of manuscript writing, 
and 3 are still recruiting participants. Details of the ReCTs 
identified are summarized in Table 3.
Discussion
Systemic therapeutic options for pNETs have dramatically 
increased during the past decade, now including SSAs and 
PRRT, targeted therapies such as everolimus and sunitinib, 
and the newly tested cytotoxic agents (i.e., capecitabine 
alone or in combination with temozolamide). These options 
can be variously employed together with surgery, locore-
gional treatments (e.g., radiofrequency ablation, cryoab-
lation, chemoembolization, and radioembolization), and/
or other drugs (e.g., diazoxide for insulinomas and proton 
pump inhibitors for gastrinomas), in a multimodal setting.
Everolimus, by targeting the mTOR pathway, provides 
a valid rationale for treating unresectable malignant NETs. 
In particular, both data derived from phase 3 trials and from 
the real-world setting witness that everolimus is effective 
and safe enough for the treatment of advanced, progressive 
G1 and G2 pNETs (Panzuto et al. 2014; Yao et al. 2010, 
2011).
However, data on pNETs therapeutic sequence are lim-
ited and clinicians have to take management decisions 
based on their own experience and/or on expert recommen-
dations. Consequently, the best place of everolimus in the 
therapeutic algorithm for advanced pNETs is still unknown.
Collectively, existing guidelines on the clinical manage-
ment of pNETs provide no definitive recommendations 
on the most suited position of everolimus in the treatment 
algorithm for advanced pNETs, apparently placing the 
drug randomly as an alternative to other choices. Simi-
larly, according to a recently published consensus article on 
the appropriateness of a variety of systemic treatments in 
patients with pNETs, everolimus, sunitinib, and cytotoxic 
chemotherapy were all defined as appropriated as the first 
line therapy in patients with hormonally functioning or pro-
gressive tumours, without significant differences in ratings 
(Strosberg et al. 2015).
As far as efficacy of everolimus in patients naïve to 
cytotoxic chemotherapy is concerned, data arising from 
prospective studies on the use of everolimus as first line 
are few. The subanalysis of the patients enrolled in the 
RADIANT-3 trial (Lombard-Bohas et al. 2015) showed 
similar efficacy in patients not chemonaïve and in 
patients chemonaïve, with a significant prolonged median 
PFS in both subgroups, and without any differences both 
in objective response and in disease control rate. How-
ever, the proportion of patients who developed grade 3–4 
thrombocytopenia was higher in the prior chemotherapy 
group. Indeed, treatment duration with everolimus was 
longer for patients who were naïve to chemotherapy, thus 
suggesting that it was better tolerated in the chemonaïve 
group. The ITMO study group (Bajetta et al. 2014) sug-
gests that combined therapy with everolimus/octreotide 
LAR can be effective as the first line for patients with 
NETs. The two studies are obviously not comparable, 
both for the different sample size and for the design of the 
study. The population of RADIANT 3 was large, with a 
long duration of disease: about 60% of the patients of the 
two arms had a duration of disease >2 years. In addition, 
the population of patients was heterogeneous in respect 
to the previous treatments. In the everolimus group, 23% 
of the patients had received radiotherapy, 49% SSAs, 
and 50% chemotherapy. During the study, best support-
ive care was also permitted, which also included SSAs in 
40% of patients. Patients with pNETs in the ITMO study 
group were only 14, recently diagnosed. None of them 
had received other medical therapies prior to the study, 
and in all cases, everolimus was associated with octreo-
tide LAR.
Panzuto et al. (2014) performed a retrospective study on 
daily clinical practice (including 85 pNETs, 66 of whom 
with G2 pNETs) to determine everolimus tolerability and 
efficacy in relation to the previous treatments. All patients 
had previously been treated with SSAs, PRRT, interferon, 
and/or systemic chemotherapy. Everolimus was associ-
ated with SSAs in 87% of patients. Higher severe toxic-
ity occurred in patients previously treated with systemic 
chemotherapy and/or PRRT, with a 12-fold increased risk 
for grade 3–4 adverse events in patients pre-treated with 
both chemotherapy and PRRT. The most frequent severe 
adverse events in this setting were haematological toxicity, 
renal failure, and peripheral oedema. According to authors, 
their findings should raise the issue of planning treatment 
with everolimus before other options, prompting the use of 
particular caution in the use of everolimus in heavily pre-
treated subjects. Conversely, a retrospective analysis by 
Kamp et al. (2013) on 24 patients treated with everolimus 
showed that the safety profile of the drug was not influ-
enced by the previous PRRT with 177Lu-octreotate (Kamp 
et al. 2013).
Even if everolimus in association with octreotide has 
been shown to improve PFS regardless of previous SSA 
exposure, patients who were naïve to SSAs experienced 
greater benefit from this association, according to a retro-
spective subset analysis of patients with advanced NETs 
in the RADIANT-2 study (Anthony et al. 2015; Shah et al. 
2011; Yao et al. 2011). These findings suggest that the 
effectiveness of everolimus could be maximized in previ-
ously untreated patients, perhaps, because they have not 
developed partial or complete resistance to SSAs, yet. 
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However, prospective data on everolimus as the first line 
therapy for pNETs, before and instead of SSAs, are too 
scarce to recommend this option.
The possibility of enhanced efficacy with SSAs com-
bined with everolimus has recently been explored in 
two randomized clinical trials, the phase 2 study COOP-
ERATE-2 (available at http://www.karger.com/Article/
Pdf/431385) and the LUNA clinical trial (available at 
http://annonc.oxfordjournals.org/content/27/suppl_6.toc). 
Preliminary results from these studies documented that 
combining everolimus and SSAs is not superior to everoli-
mus alone in progressive pNETs and progressive carcinoids 
of lung/thymus, with respect to prolongation of PFS.
Collectively, these findings seem to suggest a potential 
for the first line therapy with everolimus in patients with 
unresectable, well-differentiated, advanced pNETs.
However, these findings derive from a few studies on 
patients treated and followed-up with different protocols. 
Moreover, since these studies were not designed to evaluate 
the efficacy of everolimus first line, extrapolating any data 
on chemotherapy-naïve patients with pNETs may lead to 
biased conclusions.
Our systematic analysis of ReCTs on “Everolimus as 
first line” offers, for the first time in literature, an updated 
summary about the upcoming clinical trials.
This overview (hopefully) offers the Clinician a “glance 
into the future” about the expected effects of everolimus 
(and of the drugs used in combination with everolimus) in 
the context of the medical conditions presently under inves-
tigation (advanced/metastatic/unresectable pNETs). More-
over, the awareness of the extremely limited number of 
ongoing studies in this field (that are, additionally, almost 
all in phase 2), may encourage researchers to address new 
studies in this uncharted area.
Everolimus, beyond exerting direct antiproliferative 
effects and stimulating NETs regression, may decrease insu-
lin production and release, while inducing peripheral insulin 
resistance, with hyperglycaemia as a frequently observed 
side effect of this therapy. Conversely, patients with malig-
nant unresectable insulinomas may take great advantage of 
this effect, as shown by some retrospective studies in this 
setting (Bernard et al. 2013; Ferrer-Garcia et al. 2013). 
Therefore, everolimus could be employed as first line treat-
ment for progressive malignant insulinomas with refractory 
hypoglycaemia, as suggested by recent guidelines.
Furthermore, recently published observational data 
showed a better survival outcome in an Asian cohort of 
patients with progressive advanced GEP-NETs, most 
of pancreatic origin, if compared to the results of RADI-
ANT-3 trial or other international experiences, but quite 
similar to a subgroup analysis of Japanese patients of the 
RADIANT-3 trial itself (Ito et al. 2012b; Jiao et al. 2011; 
Liu et al. 2016). Indeed, also in the RADIANT-4 study, 
Asian patients showed a better PFS than Caucasian popula-
tion (Yao et al. 2016). It has been speculated that this eth-
nic disparity in tumour response rate can, at least in part, 
be explained by a higher frequency of activating mutations 
in the mTOR pathway in pNETs from Asian patients (Jiao 
et al. 2011; Yuan et al. 2014). In the same study, a trend 
toward a longer overall survival was observed in patients 
with liver metastases burden <10% receiving everolimus 
(Liu et al. 2016). Therefore, Asian patients with non-func-
tioning pNETs or with malignant insulinomas, but with a 
limited metastatic burden to the liver, could represent the 
ideal setting for performing prospective trials comparing 
the efficacy of everolimus as the first line in this setting, 
with respect to other drugs.
Finally, treatment strategies for advanced/metastatic 
pNETs clearly depend not only on the stage, grading, func-
tional status, the variable clinical course, and the local 
availability of different alternatives (e.g., locoregional treat-
ment skills or the opportunity to use PRRT), but also—and 
ultimately—on costs.
Conclusions
Our critical review confirms the lack of high-quality data 
to recommend everolimus as the first line therapy for 
pNETs. The ongoing clinical trials reported in this review 
will hopefully help clinicians, in the near future, to bet-
ter evaluate the role of everolimus as the first line therapy 
for pNETs. Besides, further randomized clinical trials 
will be required to confirm the promising results recently 
described by pilot studies, or derived by retrospective 
studies and subgroup analyses. However, there is already 
enough evidence to recommend everolimus as the first line 
therapy for patients with symptomatic malignant unresect-
able insulin-secreting pNETs, to control the endocrine syn-
drome regardless of tumour growth.
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